cereneo pursues excellence in clinical treatment based on newest scientific findings. As such, there is a strong research collaboration between cereneo and the newly established Lake Lucerne Institute AG (LLUI), an independent modern research facility in Vitznau. Researchers from the Neuropsychology group at LLUI perform cutting-edge science with our experienced clinicians and therapists and perform clinical trials of promising new interventions in the fields of neuropharmacology and psychotherapy in patients with neurological impairments, such as after a stroke, Parkinson, MS or TBI.

In which way does LLUI collaborate with our clinics and how do the patients at cereneo profit from this collaboration?

Presently, the Neuropsychology Research Group, in collaboration with the cereneo clinics, is preparing a clinical trial to assess the effectiveness of pro-neuroplastic substances in addressing mood disorders among neurorehabilitation patients. Additionally, the leader of the research group, Prof. Hasler, has obtained an exemption approval from the Federal Office of Public Health to administer psychedelic substances to patients on a case-by-case basis through the Compassionate Use Program. Recently, the first stroke patient suffering from depression underwent treatment with psilocybin at the cereneo clinic, which was well tolerated and yielded promising therapeutic outcomes.

Through collaborating with scientists from LLUI on the newest developments in neurorehabilitation research, we can advance diagnostics and therapies enhancing the quality of life of neurological patients by providing the best possible treatment options for each patient in our clinics.

For more information about the Neuropsychology Research Group, please click here.